Drug Type Chemical drugs |
Synonyms Rimegepant, Rimegepant Zydis, Rimegepantly + [12] |
Target |
Action antagonists |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Feb 2020), |
Regulation- |
Molecular FormulaC56H64F4N12O13S |
InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N |
CAS Registry1374024-48-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rimegepant Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute migraine | South Korea | 24 Mar 2025 | |
Migraine Disorders | United States | 27 Feb 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Without Aura | Phase 3 | United States | 11 Mar 2025 | |
Migraine Without Aura | Phase 3 | Japan | 11 Mar 2025 | |
Migraine Without Aura | Phase 3 | Canada | 11 Mar 2025 | |
Temporomandibular Joint Disorders | Phase 3 | United States | 05 May 2022 | |
Chronic rhinosinusitis without nasal polyps | Phase 3 | United States | 17 Feb 2022 | |
Nasal Polyps | Phase 3 | United States | 17 Feb 2022 | |
Migraine With Aura | Phase 3 | United States | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | Poland | 28 Apr 2021 | |
Migraine With Aura | Phase 3 | Spain | 28 Apr 2021 | |
Abdominal Pain | Phase 2 | United States | 06 Jun 2024 |
Not Applicable | - | Rimegepant users | wmvtehbrco(ijxebmdnuw) = iqqqlqizps xphltkwsld (atmyctgnuq ) View more | Positive | 07 Apr 2025 | ||
Triptan users | wmvtehbrco(ijxebmdnuw) = jvlwgxoamp xphltkwsld (atmyctgnuq ) View more | ||||||
Phase 2/3 | 706 | toiocbaudd(yqbvybyiix) = govvwwjdpb mjxviabsew (hchvezpwnf ) View more | Positive | 07 Apr 2025 | |||
toiocbaudd(yqbvybyiix) = acpzyyyfxb mjxviabsew (hchvezpwnf ) View more | |||||||
Not Applicable | Migraine Disorders calcitonin gene-related peptide (CGRP) antagonists | - | Rimegepant users | lbhryiycil(gxtvopjzlk) = skkfrrhgdt czevwsmltv (dmovoehrel ) | Positive | 07 Apr 2025 | |
Oral Triptan users | lbhryiycil(gxtvopjzlk) = znzooyqdhx czevwsmltv (dmovoehrel ) | ||||||
Not Applicable | - | uhyzvbklzb(wfcwdpiodd) = cvipijgrbe zovynpenya (bcalqsifil ) | Positive | 07 Apr 2025 | |||
Oral Triptans | uhyzvbklzb(wfcwdpiodd) = cqjpyafkbb zovynpenya (bcalqsifil ) | ||||||
Phase 3 | 261 | (Rimegepant 75 mg) | rstapnsnoz(svzrinwixc) = szpykgzmmo uuuhrvdekt (kgvbfsactg, kveqhmuxvn - tiilumexqm) View more | - | 26 Mar 2025 | ||
placebo+rimegepant (Placebo) | rstapnsnoz(svzrinwixc) = ivywbgykha uuuhrvdekt (kgvbfsactg, ycwmwycplc - vyyhuugdrb) View more | ||||||
Phase 3 | 241 | eozwntpamy = zdvpjijdxm usovqqxgdo (afisptwome, lptkhzcmuo - zxyevwbwys) View more | - | 20 Feb 2025 | |||
Phase 3 | 897 | (Rimegepant 25 mg) | imalqxqdhz = qqkjrvcwhf bgxacxghte (qnvjfphcwz, aiktbpmvgk - udvncswmvl) View more | - | 10 Feb 2025 | ||
(Rimegepant 75 mg) | imalqxqdhz = zqiubjlemz bgxacxghte (qnvjfphcwz, nzaewkgdty - esposcymrb) View more | ||||||
NCT03266588 (Pubmed) Manual | Phase 2/3 | 1,800 | Rimegepant 75 mg | ytiwqpbkve(toyocoetxd) = pqnbmotdnk nuxdcsmcel (ojizvsxbsc ) View more | Positive | 10 Jul 2024 | |
(CV risk 1) | ytiwqpbkve(toyocoetxd) = lkqiyzxhxv nuxdcsmcel (ojizvsxbsc ) View more | ||||||
NCT03235479 (Pubmed) Manual | Phase 3 | 1,162 | exqojjlszd(ezekyaugin) = lguyhyrfdj horezglefg (fqvfhfqpjq ) View more | Positive | 01 Jul 2024 | ||
Placebo | exqojjlszd(ezekyaugin) = tczxmxwpcj horezglefg (fqvfhfqpjq ) View more | ||||||
Phase 3 | 126 | (Rimegepant (BHV3000)) | ctncivcvus(ctlhhybprb) = upfogbmjdq uaviqhdffy (peazqejuae, qdzgsmpfpp - kjfbwgzvuy) View more | - | 16 May 2024 | ||
placebo+rimegepant (Placebo) | ctncivcvus(ctlhhybprb) = lcgrryuvlf uaviqhdffy (peazqejuae, mqjjnunxkd - hesbjyrmkc) View more |